• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

    82.14 -0.85 (-1.02%)
    Streaming Delayed Price Updated: 1:35 PM EST, Feb 19, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 145,370
    Open 81.88
    Bid (Size) 82.03 (100)
    Ask (Size) 82.40 (100)
    Prev. Close 82.99
    Today's Range 80.59 - 83.09
    52wk Range 33.70 - 96.54
    Shares Outstanding 62,107,572
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance ↗
    This clinical-stage biotech focused on peptide therapeutics reported significant insider selling amid a year of strong stock performance. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes ↗
    The chief medical officer at one of the top pharmaceutical companies sold nearly 10,000 shares in late January 2026, but the reason was for something very simple. 
    Via The Motley Fool
    Topics Regulatory Compliance

    Performance

    YTD
    -5.8%
    -5.8%
    1 Month
    -1.5%
    -1.5%
    3 Month
    -3.5%
    -3.5%
    6 Month
    +46.1%
    +46.1%
    1 Year
    +117.6%
    +117.6%

    More News

    Read More
    News headline image
    "Animal Spirits" Return: Morgan Stanley Signals M&A Renaissance as Healthcare and Industrials Lead Shifting Landscape
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    BMO Capital Lifts Protagonist Therapeutics Target On J&J Deal Hopes — Retail Traders Pile In ↗
    Via Stocktwits
    News headline image
    Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
    Via ACCESS Newswire
    News headline image
    Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    News headline image
    Protagonist (PTGX) Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice
    Via ACCESS Newswire
    News headline image
    Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    Via ACCESS Newswire
    News headline image
    Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting
    Via ACCESS Newswire
    News headline image
    What 7 Analyst Ratings Have To Say About Protagonist Therapeutics ↗
    Via Benzinga
    News headline image
    Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences
    Via ACCESS Newswire
    News headline image
    Moody Aldrich Dumps Entire Stake in Chart Industries Worth $5.8 Million ↗
    Via The Motley Fool
    Topics Energy
    News headline image
    Moody Aldrich Fully Exits 136K SKWD Shares Worth $7.8 Million ↗
    Via The Motley Fool
    News headline image
    Moody Aldrich Liquidates Entire Stake in PLMR Worth $8.2 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    Big Pharma Just Put Peptides Back on the Map – Which Players Are Still Under the Radar?
    Via AB Newswire
    News headline image
    2 Top Dividend Kings Every Income Investor Should Own ↗
    Via The Motley Fool
    Topics Bonds
    News headline image
    Johnson & Johnson's M&A Strategy Is the Real Story for Investors ↗
    Via MarketBeat
    News headline image
    Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook ↗
    Via Benzinga
    News headline image
    Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print ↗
    Via Stocktwits
    Topics Government World Trade
    News headline image
    Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch ↗
    Via Benzinga
    News headline image
    FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy ↗
    Via Benzinga
    News headline image
    Wall Street Suffers Worst Day Since April as Trump Revives Trade War Fears ↗
    Via Chartmill
    Topics Artificial Intelligence Government World Trade
    News headline image
    Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today ↗
    Via The Motley Fool
    News headline image
    Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
    Via Chartmill

    Frequently Asked Questions

    Is Protagonist Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Protagonist Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Protagonist Therapeutics, Inc. - Common Stock trade on?
    Protagonist Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Protagonist Therapeutics, Inc. - Common Stock?
    The ticker symbol for Protagonist Therapeutics, Inc. - Common Stock is PTGX on the Nasdaq Stock Market
    What is the current price of Protagonist Therapeutics, Inc. - Common Stock?
    The current price of Protagonist Therapeutics, Inc. - Common Stock is 82.14
    When was Protagonist Therapeutics, Inc. - Common Stock last traded?
    The last trade of Protagonist Therapeutics, Inc. - Common Stock was at 02/19/26 01:35 PM ET
    What is the market capitalization of Protagonist Therapeutics, Inc. - Common Stock?
    The market capitalization of Protagonist Therapeutics, Inc. - Common Stock is 5.10B
    How many shares of Protagonist Therapeutics, Inc. - Common Stock are outstanding?
    Protagonist Therapeutics, Inc. - Common Stock has 5B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.